A Preliminary Study for the Assessment of PD-L1 and PD-L2 on Circulating Tumor Cells by Microfluidic-Based Chipcytometry

References

• Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32(10), 1020–1030 (2014).
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568–571 (2014).
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 27(7), 1362 (2016).
   PubMed Web of Science ®Google Scholar
• Friedman CF, Postow MA. Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition. Curr. Oncol. Rep. 18(4), 21 (2016).
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20(19), 5064–5074 (2014).
   PubMed Web of Science ®Google Scholar
• US FDA approves Keytruda for advanced non-small-cell lung cancer (2015). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm.
   Google Scholar
• Madore J, Vilain RE, Menzies AM et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 28(3), 245–253 (2015).
   PubMed Web of Science ®Google Scholar
• Jilaveanu LB, Shuch B, Zito CR et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J. Cancer 5(3), 166–172 (2014).
   PubMed Web of Science ®Google Scholar
• Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403–6409 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(19), 3213–3221 (2008).
   PubMed Web of Science ®Google Scholar
• De Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302–6309 (2008).
   PubMed Web of Science ®Google Scholar
• Mazel M, Jacot W, Pantel K et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol. Oncol. 9(9), 1773–1782 (2015).
   PubMed Web of Science ®Google Scholar
• Schehr JL, Schultz ZD, Warrick JW et al. High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1. PLoS ONE 11(7), e0159397 (2016).
   PubMed Web of Science ®Google Scholar
• Satelli A, Batth IS, Brownlee Z et al. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci. Rep. 6, 28910 (2016).
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat. Rev. Cancer 14(9), 623–631 (2014).
   PubMed Web of Science ®Google Scholar
• Wang X, Sun Q, Liu Q, Wang C, Yao R, Wang Y. CTC immune escape mediated by PD-L1. Med. Hypotheses 93, 138–139 (2016).
   PubMed Web of Science ®Google Scholar
• Nicolazzo C, Raimondi C, Mancini M et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab. Sci. Rep. 6, 31726 (2016).
   PubMed Web of Science ®Google Scholar
• Warkiani ME, Khoo BL, Wu L et al. Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics. Nat. Protoc. 11(1), 134–148 (2016).
   PubMed Web of Science ®Google Scholar
• Hou HW, Warkiani ME, Khoo BL et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci. Rep. 3, 1259 (2013).
   PubMed Web of Science ®Google Scholar
• Warkiani ME, Khoo BL, Tan DS et al. An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. Analyst 139(13), 3245–3255 (2014).
   PubMed Web of Science ®Google Scholar
• Khoo BL, Warkiani ME, Tan DS et al. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PLoS ONE 9(7), e99409 (2014).
   PubMed Web of Science ®Google Scholar
• Hennig C, Adams N, Hansen G. A versatile platform for comprehensive chip-based explorative cytometry. Cytometry 75(4), 362–370 (2009).
   PubMedGoogle Scholar
• Stanciu LA, Bellettato CM, Laza-Stanca V, Coyle AJ, Papi A, Johnston SL. Expression of programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulator ligand on human respiratory tract epithelial cells and regulation by respiratory syncytial virus and type 1 and 2 cytokines. J. Infect. Dis. 193(3), 404–412 (2006).
   PubMed Web of Science ®Google Scholar
• Azuma K, Ota K, Kawahara A et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 25(10), 1935–1940 (2014).
   PubMed Web of Science ®Google Scholar
• Maecker HT, Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry 69(9), 1037–1042 (2006).
   PubMedGoogle Scholar
• Allan AL, Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J. Oncol. 2010, 426218 (2010).
   PubMedGoogle Scholar
• Pinato DJ, Shiner RJ, White SD et al. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: implications for immunotherapy. Oncoimmunology 5(9), e1213934 (2016).
   PubMed Web of Science ®Google Scholar